Analysis of demographic, clinical and laboratory parameters in COVID-19 patients with acute kidney injury
- Authors: Abdurakhimov A.K.1
-
Affiliations:
- Andijan State Medical Institute
- Issue: Vol 17, No 1 (2025)
- Pages: 33-36
- Section: Original Articles
- URL: https://journal-vniispk.ru/2075-3594/article/view/293198
- DOI: https://doi.org/10.18565/nephrology.2025.1.33-36
- ID: 293198
Cite item
Open Access
Access granted
Subscription Access
Abstract
Objective: Improvement of understanding of risk predictors of renal complications after COVID-19 in patients with and without diabetes mellitus (DM), which will allow developing effective prevention and treatment strategies.
Material and methods. The study included 386 patients who were divided into groups depending on the glomerular filtration rate (SFR) calculated using the CKD-EPI formula. Patients were classified as having normal renal function (≥90 ml/min/1.73 m2) and impaired renal function (≤89 ml/min/1.73 m2).
Results. Patients with impaired renal function were significantly older, had higher body mass index (BMI) and lung injury compared to patients with normal renal function. Patients with decreased GFR had hematological abnormalities, such as increased hematocrit and decreased lymphocyte count. These changes were especially pronounced in men and diabetic patients, indicating possible inflammatory and metabolic effects on kidney injury in these groups.
Conclusion. Older age, increased BMI and signigicant lung injury were significant predictors of renal injury in patients with COVID-19, especially in diabetic patients. Regular assessment of GFR and early management of inflammatory processes may be key to preventing renal complications in this category of patients.
Full Text
##article.viewOnOriginalSite##About the authors
Abduhalim Kh. Abdurakhimov
Andijan State Medical Institute
Author for correspondence.
Email: abduhalimaka@mail.ru
ORCID iD: 0000-0003-4541-0436
Teaching Assistant of the Department
Uzbekistan, AndijanReferences
- Jewell P.D., Bramham K., Galloway J., et al. COVID-19-related acute kidney injury; incidence, risk factors and outcomes in a large UK cohort. BMC. Nephrol. 2021;22:359. Doi: https://doi.org/10.1186/s12882-021-02557-x.
- Sohrabi M.R., Amin R., Maher A., et al. Sociodemographic determinants and clinical risk factors associated with COVID-19 severity: a cross-sectional analysis of over 200,000 patients in Tehran, Iran. BMC. Infect. Dis. 2021;21:474. Doi: https://doi.org/10.1186/s12879-021-06179-4.
- Wang Q., Cheng J., Shang J., et alClinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study. BMJ. Open. 2021;11:e043790. doi: 10.1136/bmjopen-2020-043790.
- Lowe R., Ferrari M., Nasim-Mohi M., et al. Clinical characteristics and outcome of critically ill COVID-19 patients with acute kidney injury: a single centre cohort study. BMC. Nephrol. 2021;22:92. Doi: https://doi.org/10.1186/s12882-021-02296-z.
- de Almeida D.C., Franco M.D.C.P., Dos Santos D.R.P., et al. Acute kidney injury: Incidence, risk factors, and outcomes in severe COVID-19 patients. PLoS One. 2021;16(5):e0251048. doi: 10.1371/journal.pone.0251048. [PMID: 34033655, PMCID: PMC8148326].
- Chidambaram V., Tun N.L., Haque W.Z., et al. Factors associated with disease severity and mortality among patients with COVID-19: A systematic review and meta-analysis. PLoS One. 2020;15(11):e0241541. doi: 10.1371/journal.pone.0241541. [PMID: 33206661, PMCID: PMC7673562].
- Yang Q., Yang X. Incidence and risk factors of kidney impairment on patients with COVID-19: A meta-analysis of 10180 patients. PLoS One. 2020;15(11):e0241953. doi: 10.1371/journal.pone.0241953. [PMID: 33196669, PMCID: PMC7668576].
- Lin L., Wang X., Ren J., et al. Risk factors and prognosis for COVID-19-induced acute kidney injury: a meta-analysis. BMJ. Open. 2020;10(11):e042573. doi: 10.1136/bmjopen-2020-042573. [PMID: 33172950, PMCID: PMC7656886].
- Abdurakhimov A., Kakharov Z. Pathogenetic role of coronavirus infection in the devel-opment of acute kidney injury. Am. J. Med. Med. Sci. 2024;14(6): 1673–9. Doi: https://doi.org/10.5923/j.ajmms.20241406.44.
- Shlipak M.G., Tummalapalli S.L., Boulware L.E., et al. Conference Participants. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2021;99(1):34–47. doi: 10.1016/j.kint.2020.10.012. [Epub 2020 Oct 27, PMID: 33127436].
- Anaya J.M., Rojas M., Salinas M.L., et al. Post-COVID study group; Monsalve DM, Acosta-Ampudia Y, Ramírez-Santana C. Post-COVID syndrome. A case series and comprehensive review. Autoimmun. Rev. 2021;20(11):102947. doi: 10.1016/j.autrev.2021.102947. [Epub 2021 Sep 10, PMID: 34509649, PMCID: PMC8428988].
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117–314. doi: 10.1016/j.kint.2023.10.018. [PMID: 38490803].
- Messersmith J., Stoddart-Osumah C., Lennon M., Wirtz D. Emergency seed funding for COVID-19 research: lessons from Johns Hopkins University. J. Clin. Invest. 2021;131(1):e145615. doi: 10.1172/JCI145615. [PMID: 33170810, PMCID: PMC7773385].
Supplementary files
